New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder

Journal of the American Geriatrics Society

Volumn 60, Issue 3, 2012, Pages 474-479

  Erickson, Sara C ^a   Le, Lisa ^a   Zakharyan, Armen ^a   Stockl, Karen M ^a   Harada, Ann S M ^a   Borson, Soo ^b   Ramsey, Scott D ^c   Curtis, Bradford ^a  

^a OPTUM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

atypical antipsychotics; diabetes mellitus; elderly; hyperlipidemia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

AGED; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GERIATRIC PATIENT; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; SCHIZOPHRENIA; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; SCHIZOPHRENIA; UNITED STATES;

EID: 84858336914     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03842.x     Document Type: Article

References (27)

1. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008; 101: 295-303.
2. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98: 247-252.
3. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008; 28: 132-137.
4. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry 2006; 67: 1055-1061.
5. Brooks JO, Chang HS, Krasnykh O,. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatr Rep 2009; 11: 33-40.
6. Cascade E, Kalali AH, Cummings JL,. Use of atypical antipsychotics in the elderly. Psychiatry (Edgemont) 2008; 5: 28-31.
7. Sicras-Mainar A, Blanca-Tomayo M, Regas-Gutierrez J, et al. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database. Eur Psychiatry 2008; 23: 100-108.
8. Mathys M, Balszczyk A, Busti A,. Incidence of abnormal metabolic parameters and weight gain induced by atypical antipsychotics in elderly patients with dementia. Consult Pharm 2009; 24: 201-209.
9. Albert SG, Grossberg GT, Thaipisuttikul PJ, et al. Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: A retrospective nursing home chart review study. J Am Med Dir Assoc 2009; 10: 115-119.
10. Etminan M, Streiner DL, Rochon PA,. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003; 23: 1411-1415.
11. Barnett M, Argo T, Alexander B, et al. A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors. Ann Clin Psychiatry 2006; 18: 1-7.
12. Zheng L, Mack WJ, Dagerman KS, et al. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: The CATIE-AD Study. Am J Psychiatry 2009; 166: 583-590.
13. Rabins PV, Blacker D, Rovner BW, et al. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias [on-line]. Arlington (VA): American Psychiatric Association, 2007. Available at. Accessed March 5, 2010.
14. Rocha FL, Hara C, Ramos ML, et al. An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord 2006; 22: 445-448.
15. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613-619.
16. Centers for Disease Control and Prevention. Percentage of civilian, noninstitutionalized population with diagnosed diabetes, by age, United States, 1980-2007 [on-line] July 29, 2009. Available at. Accessed March 9, 2010.
17. American Diabetes Association. Diabetes statistics [on-line]. Available at. Accessed March 9, 2010.
18. Rockwood K, Awalt E, MacKnight C, et al. Incidence and outcomes of diabetes mellitus in elderly people: Report from the Canadian Study of Heath and Aging. Can Med Assoc J 2000; 162: 769-772.
19. Bourdel-Marchasson I, Dubroca B, Letenneur L, et al. Incidence and predictors of drug-treated diabetes in elderly French subjects. The PAQUID epidemiological survey. Diabet Med 2000; 17: 675-681.
20. Ferrara A, Barrett-Connor E, Shan J,. Total, LDL, and HDL cholesterol decrease with age in older men and women: The Rancho Bernardo Study 1984-1994. Circulation 1997; 96: 37-43.
21. Rosack J,. FDA to require diabetes warning on antipsychotics. Psychiatric News 2003; 38: 1.
22. U.S. Food and Drug Administration. Warning about hyperglycemia and atypical antipsychotic drugs. FDA Safety News [on-line] June 2004. Available at. Accessed March 11, 2010.
23. Komossa K, Rummel-Kluge C, Schmid F, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 3: CD006654.
24. Komassa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; 4: CD006569.
25. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008; 101: 273-286.
26. Brown RR, Estoup MW,. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005; 20: 105-112.
27. Simon V, van Winkel R, De Hert M,. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 10: 1041-1050.